The European Parliament has given the go-ahead to "Horizon 2020", the EU's most ambitious research and innovation program to date. With a budget of almost €80bn over seven years, the program includes public-private partnerships in areas such as novel medicines, biomarkers and diagnostics.
The European Parliament has given the go-ahead to "Horizon 2020", the EU's most ambitious research and innovation program to date. With a budget of almost €80bn over seven years, the program includes public-private partnerships in areas such as novel medicines, biomarkers and diagnostics.
Horizon 2020, which is expected to be approved by EU member states next month, will succeed the current seventh framework research programme (FP7) from next year
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
